Avanir Pharmaceuticals (AVN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Avanir Pharmaceuticals (AVN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mickey911 who started this subject	5/29/2002 2:07:15 AM
From: luis a. garcia	Read Replies (1) of 166

Abreva Canadian approval is at hand. ADD 30 million new Abreva customers. ROW will follow along, Korea,Israel this year. Abreva revenue is increasing and has room to grow. Neurodex clinical trials concluded enrollment phase II-III emotional lability, results out in July. Partner sought for Neurodex that means infusion of research dollars to carry on to phase III for that drug. New IND for IgE to be filed later this year after conclusion of tox studies. Phase I IgE will start soon after that. Phase III Neurodex trial starting this fall. Mab production contract phaseII for EOS and Peregrine due any day now. Large new partnership with DNAX Shering Ploug now in phase I development. Abreva genital grant to study application to genital herpes 1.2 million. Shangai biotech in china conducting clinical trials for Abreva genital formulation. Xenerex application to fight Bioterror grant application to develop mab to fend off infectious disease. applied for. MiH inhibitor lead candidates now being patented. MiH program progressing far along. Xenerex developing 8 targets in house to outlicence and or develop internally. Gents with a bit of luck this stock is going places. luis

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next